CL2022003404A1 - Rhabdovirus recombinante que codifica una proteína de fusión fc de dominio extracelular cd80 - Google Patents
Rhabdovirus recombinante que codifica una proteína de fusión fc de dominio extracelular cd80Info
- Publication number
- CL2022003404A1 CL2022003404A1 CL2022003404A CL2022003404A CL2022003404A1 CL 2022003404 A1 CL2022003404 A1 CL 2022003404A1 CL 2022003404 A CL2022003404 A CL 2022003404A CL 2022003404 A CL2022003404 A CL 2022003404A CL 2022003404 A1 CL2022003404 A1 CL 2022003404A1
- Authority
- CL
- Chile
- Prior art keywords
- fusion protein
- extracellular domain
- recombinant rhabdovirus
- recombinant
- encoding
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/766—Rhabdovirus, e.g. vesicular stomatitis virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20041—Use of virus, viral particle or viral elements as a vector
- C12N2760/20043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20241—Use of virus, viral particle or viral elements as a vector
- C12N2760/20243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20241—Use of virus, viral particle or viral elements as a vector
- C12N2760/20245—Special targeting system for viral vectors
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente invención se refiere al campo de los virus oncolíticos y, en particular, a un rhabdovirus recombinante, tal como un virus de estomatitis vesicular, que codifica en su genoma una proteína de fusión Fc de dominio extracelular CD80. Asimismo, la invención se refiere al uso del virus recombinante en el tratamiento del cáncer, y también a métodos para producir tales virus.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20178032 | 2020-06-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2022003404A1 true CL2022003404A1 (es) | 2023-06-16 |
Family
ID=71092238
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2022003404A CL2022003404A1 (es) | 2020-06-03 | 2022-12-01 | Rhabdovirus recombinante que codifica una proteína de fusión fc de dominio extracelular cd80 |
Country Status (19)
Country | Link |
---|---|
US (1) | US20210379130A1 (es) |
EP (1) | EP4161544A1 (es) |
JP (1) | JP2023527577A (es) |
KR (1) | KR20230020501A (es) |
CN (1) | CN115916231A (es) |
AR (1) | AR122515A1 (es) |
AU (1) | AU2021285068A1 (es) |
BR (1) | BR112022023753A2 (es) |
CA (1) | CA3185332A1 (es) |
CL (1) | CL2022003404A1 (es) |
CO (1) | CO2022017351A2 (es) |
CR (1) | CR20220606A (es) |
DO (1) | DOP2022000273A (es) |
EC (1) | ECSP22092003A (es) |
IL (1) | IL298648A (es) |
MX (1) | MX2022015261A (es) |
PE (1) | PE20231293A1 (es) |
TW (1) | TW202210499A (es) |
WO (1) | WO2021245111A1 (es) |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI2161336T1 (sl) | 2005-05-09 | 2013-11-29 | Ono Pharmaceutical Co., Ltd. | Humana monoklonska protitelesa za programirano smrt 1 (PD-1) in postopki za zdravljenje raka ob uporabi anti-PD-1 protiteles samih ali v kombinaciji z drugimi imunoterapevtiki |
PE20110218A1 (es) | 2006-08-02 | 2011-04-01 | Novartis Ag | DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS |
EP2535354B1 (en) | 2007-06-18 | 2017-01-11 | Merck Sharp & Dohme B.V. | Antibodies to human programmed death receptor pd-1 |
KR20110004354A (ko) * | 2007-12-21 | 2011-01-13 | 와이어쓰 엘엘씨 | 유전자 변형된 약독화 수포성 구내염 바이러스, 이의 조성물 및 사용 방법 |
CN104548091A (zh) | 2008-02-11 | 2015-04-29 | 治疗科技公司 | 用于肿瘤治疗的单克隆抗体 |
US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
DE102008050860A1 (de) | 2008-10-08 | 2010-04-15 | Dorothee Von Laer | LCMV-GP-VSV-Pseudotypvektoren und tumorinfiltrierende Virenproduzentenzellen zur Therapie von Tumoren |
US8859541B2 (en) | 2012-02-27 | 2014-10-14 | Boehringer Ingelheim International Gmbh | 6-alkynylpyridines |
US9278978B2 (en) | 2013-08-23 | 2016-03-08 | Boehringer Ingelheim International Gmbh | 6-Alkynyl Pyridine |
US9249151B2 (en) | 2013-08-23 | 2016-02-02 | Boehringer Ingelheim International Gmbh | Bis-amido pyridines |
WO2015077714A1 (en) * | 2013-11-22 | 2015-05-28 | Yale University | Chimeric vsv virus compositions and methods of use thereof for treatment of cancer |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
AR101479A1 (es) | 2014-08-11 | 2016-12-21 | Boehringer Ingelheim Int | Derivados de 6-alquinil-piridina |
CN114272371A (zh) | 2015-07-29 | 2022-04-05 | 诺华股份有限公司 | 包含抗pd-1抗体分子的联合疗法 |
US10273281B2 (en) | 2015-11-02 | 2019-04-30 | Five Prime Therapeutics, Inc. | CD80 extracellular domain polypeptides and their use in cancer treatment |
WO2017143449A1 (en) * | 2016-02-24 | 2017-08-31 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Smc combination therapy for the treatment of cancer |
MA43552A (fr) | 2016-04-15 | 2018-11-07 | Alpine Immune Sciences Inc | Protéines immunomodulatrices à variants de cd80 et leurs utilisations |
LT3458478T (lt) | 2016-05-18 | 2021-02-10 | Boehringer Ingelheim International Gmbh | Antikūnai prieš pd-1 ir lag-3, skirti vėžio gydymui |
EP3458576A4 (en) * | 2016-05-19 | 2020-03-25 | Turnstone Limited Partnership | PSEUDOTYPED ONCOLYTIC RHABDOVIRUSES AND THEIR USE IN POLYTHERAPY |
BR112019018747A2 (pt) * | 2017-03-16 | 2020-05-05 | Alpine Immune Sciences Inc | proteínas imunomoduladoras variantes de cd80 e usos das mesmas |
CN108728488A (zh) * | 2017-04-19 | 2018-11-02 | 生命序有限公司 | 溶瘤病毒构建体、溶瘤病毒及其应用 |
CN112543642A (zh) * | 2018-08-29 | 2021-03-23 | 戊瑞治疗有限公司 | CD80胞外结构域Fc融合蛋白给药方案 |
TW202106703A (zh) * | 2019-04-26 | 2021-02-16 | 中國大陸商北京軒義醫藥科技有限公司 | Cd80變體蛋白及其用途 |
-
2021
- 2021-06-02 MX MX2022015261A patent/MX2022015261A/es unknown
- 2021-06-02 TW TW110119935A patent/TW202210499A/zh unknown
- 2021-06-02 CA CA3185332A patent/CA3185332A1/en active Pending
- 2021-06-02 KR KR1020237000146A patent/KR20230020501A/ko unknown
- 2021-06-02 US US17/336,351 patent/US20210379130A1/en active Pending
- 2021-06-02 CR CR20220606A patent/CR20220606A/es unknown
- 2021-06-02 EP EP21730192.8A patent/EP4161544A1/en active Pending
- 2021-06-02 AR ARP210101510A patent/AR122515A1/es unknown
- 2021-06-02 PE PE2022002825A patent/PE20231293A1/es unknown
- 2021-06-02 IL IL298648A patent/IL298648A/en unknown
- 2021-06-02 AU AU2021285068A patent/AU2021285068A1/en active Pending
- 2021-06-02 BR BR112022023753A patent/BR112022023753A2/pt unknown
- 2021-06-02 JP JP2022574112A patent/JP2023527577A/ja active Pending
- 2021-06-02 WO PCT/EP2021/064728 patent/WO2021245111A1/en unknown
- 2021-06-02 CN CN202180039769.2A patent/CN115916231A/zh active Pending
-
2022
- 2022-12-01 CL CL2022003404A patent/CL2022003404A1/es unknown
- 2022-12-01 CO CONC2022/0017351A patent/CO2022017351A2/es unknown
- 2022-12-01 DO DO2022000273A patent/DOP2022000273A/es unknown
- 2022-12-02 EC ECSENADI202292003A patent/ECSP22092003A/es unknown
Also Published As
Publication number | Publication date |
---|---|
CR20220606A (es) | 2023-01-23 |
PE20231293A1 (es) | 2023-08-22 |
DOP2022000273A (es) | 2023-01-15 |
KR20230020501A (ko) | 2023-02-10 |
EP4161544A1 (en) | 2023-04-12 |
TW202210499A (zh) | 2022-03-16 |
CA3185332A1 (en) | 2021-12-09 |
IL298648A (en) | 2023-01-01 |
CO2022017351A2 (es) | 2022-12-20 |
BR112022023753A2 (pt) | 2022-12-20 |
MX2022015261A (es) | 2023-03-14 |
JP2023527577A (ja) | 2023-06-29 |
ECSP22092003A (es) | 2023-01-31 |
CN115916231A (zh) | 2023-04-04 |
AR122515A1 (es) | 2022-09-14 |
AU2021285068A1 (en) | 2023-01-19 |
WO2021245111A1 (en) | 2021-12-09 |
US20210379130A1 (en) | 2021-12-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2020000050A (es) | Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos | |
CL2018000740A1 (es) | Vectores del factor viii del virus adeno-asociado, partículas víricas asociadas y formulaciones terapéuticas que los comprenden | |
CL2018000587A1 (es) | Adenovirus oncolítico que codifica una proteína b7 (divisional de sol. n° 2731-2017) | |
UY35266A (es) | Compuestos antivirales | |
EA201891415A8 (ru) | Антигены вируса иммунодефицита человека, векторы, композиции и способы их применения | |
CO2021009271A2 (es) | Rhabdovirus recombinante que codifica ccl21 | |
ECSP10010287A (es) | Vectores de virus oncolíticos de viruela | |
ECSP19018654A (es) | Anticuerpos contra el virus del dengue, polipeptidos que contienen regiones fc variantes, y métodos de uso | |
CL2017003144A1 (es) | Péptidos lipidados resistentes a proteasas | |
DOP2010000251A (es) | Paramyxovirus eficaz como antitumoral | |
ECSP17075380A (es) | Fusiones de variante iii del receptor de factor de crecimiento epidérmico-mesotelina y métodos para usar los mismos | |
UY37198A (es) | Vacuna universal para enfermedades virales | |
CY1124507T1 (el) | Νεος αναστολεας μεκ για τη θεραπευτικη αγωγη των ιικων και βακτηριακων λοιμωξεων | |
CO2021007958A2 (es) | Virus del herpes aviar recombinantes que contienen múltiples genes extraños | |
CO2022003004A2 (es) | Virus vaccinia oncolíticos genéticamente diseñados y métodos para usar los mismos | |
CO2018001339A2 (es) | Sistema vector de adenovirus aviar 9 (fadv-9) y métodos asociados | |
CO2022017351A2 (es) | Rhabdovirus recombinante que codifica una proteína de fusión fc de dominio extracelular cd80 | |
CO2023017249A2 (es) | Proteínas de fusión tnfsf-l y usos de las mismas | |
UY35418A (es) | Vacuna que proporciona protección frente a diferentes Picornavirus humanos. | |
AR117808A1 (es) | Virus de vacuna recombinante y métodos de uso del mismo | |
ECSP23024245A (es) | Construcciones de ácido nucleico, vectores virales y partículas virales | |
AR105615A1 (es) | Fusiones de variante iii del receptor de factor de crecimiento epidérmico-mesotelina y métodos para usar los mismos | |
ECSP14012622A (es) | Compuestos antivirales | |
CR20140021A (es) | Compuestos antivirales | |
CL2010001151A1 (es) | Formulacion que comprende los segmentos proteicos nhe, che, nnp, m1 y fp2 del virus isa; vacuna recombinante que la comprende; procedimiento de preparacion; y uso para prevenir o tratar infeccion por virus isa. |